Keywords: Merck Serono, Compugen, Merck KGaA, Neviah Genomics, Novel biomarkets, Joint venture, Israel

Compugen and Merck Serono set up biomarker company Neviah Genomics

Article | 25 June 2012

Print This

German drug major Merck KGaA’s (MRK: DE) Merck Serono division and Israel-based Compugen (Nasdaq: CGEN) have established Neviah ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in